This is training exercise designed to bring HIV vaccine research information to life.
AIDS Vaccine Science: Hot Seat
After FACTS: What’s next for HIV prevention in women?
FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. In this webinar, we discussed what these and other data meant for women, including young and adolescent girls.
Selected Guide to Pipeline of Antibodies, Long-Acting ARVs and Vaccines
This graphic provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
Success with PrEP: Next Steps to Support Policy Decisions in Southern and East Africa
Convened on 26 October 2014 by AVAC, UNAIDS and WHO, this meeting brought together representatives of ministries of health and national AIDS councils, PrEP researchers and participants from research and demonstration sites where PrEP is currently being delivered in Kenya, Mozambique, South Africa, Uganda and Zimbabwe, along with funders, manufacturers and HIV advocates and activists. Through a series of presentations, moderated discussions and small group work, participants shared current experiences and helped define a structured approach to considering the integration of PrEP in HIV prevention programs in the region. In addition, some of the knowledge gaps that remain to be researched were identified.
Px Wire April-June 2015, Vol. 8, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, you’ll find updates and how WHO is approaching broader guidance on oral PrEP and a closer look at passive immunization.
Our centerspread provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
Proceedings from the Workshop on Alternative Trial Designs for Microbicides
CONRAD, AVAC and the Forum for Collaborative HIV Research convened a workshop on alternative trial designs for microbicides which generated lively discussion among more than 60 participants.
Slides from the Workshop on Alternative Trial Designs for Microbicides
CONRAD, AVAC and the Forum for Collaborative HIV Research convened a workshop on alternative trial designs for microbicides which generated lively discussion among more than 60 participants. All slide presentations from the workshop are included.
AVAC Report 2014/15: HIV Prevention on the Line
In AVAC Report 2014/15: HIV Prevention on the Line, we take on the current state of global targets for the AIDS response, looking beyond pithy slogans to explore what’s in place and what’s not in terms of targets, resources and action to begin to end the AIDS epidemic. We also provide concise updates and calls to action on key prevention interventions including AIDS vaccines, voluntary medical male circumcision, microbicides, PrEP, and hormonal contraception use and HIV risk.
Intervention Update: Hormonal Contraception and HIV
Excerpted from AVAC Report: HIV Prevention on the Line, this update describes recent discussion and analysis in the search for answers as to whether hormonal contraceptives, including long-acting methods such as Depo-Provera (DPMA) and other injectable contraceptives and the implant, affect women’s risk of acquiring HIV.
Intervention Update: Voluntary Medical Male Circumcision
Excerpted from AVAC Report: HIV Prevention on the Line, this update cites the success of a previous VMMC target and suggests the current lack of a target moving forward will stifle continued progress.